Beta Amyloid Peptide: Research Paper : Causes of death in a nationwide cohort of community-dwellers with Alzheimer's disease

Causes of death in a nationwide cohort of community-dwellers with Alzheimer's disease

Abstract

Background: Alzheimer's disease (AD) is related to higher mortality but it is not entirely evident which causes of death explain this. The objective of this study was to assess the causes of death in a nationwide cohort of clinically verified AD cases and compare the causes to a matched comparison cohort without AD.

Methods: Cohort of all community-dwellers with clinically verified AD residing in Finland on 31 December 2005 (n = 27,948) and a matched comparison cohort without AD (n = 27,948). Mortality (2006-2012, n = 30,641, 54.8%) and causes of death were obtained from register. Cause of death was ascertained with clinical examination (87.3% of deaths), forensic (8.0%) or medical autopsy (4.7%).

Results: In AD cohort, the most common causes were diseases of the nervous system (49.9%), circulatory system (31.7%) and neoplasms (7.7%), while diseases of circulatory system (53.5%), neoplasms (19.1%) and mental and behavioral disorders (7.3%) contributed for majority of deaths in the comparison cohort. There were no sex-wise differences. People with AD were over 20 times more likely to die due to diseases of the nervous system (OR, 95% CI 22.06, 19.87-24.25) than the comparison cohort, while other causes, e.g., diseases of the circulatory system (0.40, 0.38-0.42), neoplasms (0.35, 0.33-0.38), mental and behavioral disorders (0.27, 0.24-0.30) and external causes of morbidity and mortality (0.72, 0.62-0.81) were less common in the AD cohort.

Conclusions: Although half of the people with AD died due to diseases of the nervous system, cancers and especially cardio/cerebrovascular diseases were still important contributors to the overall mortality among them. This should be acknowledged when planning their terminal care.

Keywords: Alzheimer's disease; Causes of death; Cohort; Mortality.

Conflict of interest statement

AMT, MK and SH report no competing interests. HT and JT have participated in research projects funded by Janssen-Cilag and Eli Lilly with grants to the institution where they are employed. JT has received personal fees from the Finnish Medicines Agency (Fimea), European Medicines Agency (EMA), Eli Lilly, Janssen-Cilag, Lundbeck, and Otsuka; and has received grants from the Stanley Foundation and Sigrid Jusélius Foundation.

This article originally appeared in the "https://pubmed.ncbi.nlm.nih.gov/33138782/" and has their copyrights. We do not claim copyright on the content. This information is for research purposes only. This Blog is made available by publishers for educational purposes only as well as to give you general information and a general understanding , not to provide specific advice. By using this blog site you understand that there is no client relationship between you and the Blog publisher. The Blog should not be used as a substitute for competent research advice.